Purple Biotech Reports IM1240 Activity in Treatment-Resistant Cancer Models
Purple Biotech, based in Rehovot, released preclinical findings on November 20 on its experimental cancer antibody IM1240. The company reported tumor-killing activity in human tumor models resistant to immunotherapy-containing treatments. It issued the results in connection with the EORTC-NCI-AACR symposium in Barcelona, Spain. Amir Horowitz, an associate professor at the Icahn School of Medicine at Mount Sinai and the named presenter, said: “The activity observed in treatment-resistant human tumor models is particularly encouraging and warrants further investigation.” The experiments included six metastatic head-and-neck cancer lymph-node samples, one bladder-cancer specimen resistant to enfortumab vedotin plus pembrolizumab, and one lung-cancer specimen resistant to chemotherapy plus PD-1 blockade. In the lung-cancer tissue explant, the company reported an in situ pathological-response score of 94 on a 0–100 scale. The corresponding scores were 49 for a comparable antibody with an inactive NKG2A arm and 38 for a control whose cap could not be removed. In dissociated head-and-neck and bladder samples, tumor killing depended on both the CD3 and NKG2A arms functioning. IM1240 combines a 5T4 tumor-targeting arm with a CD3 arm that engages T cells and an NKG2A arm that engages natural killer cells and blocks an inhibitory immune checkpoint. Its CD3 arm is capped during circulation. The design aims to let enzymes in the tumor environment remove that cap and enable T-cell activation locally. Activity in cancer cell lines depended on expression of the 5T4 target. The company said the findings build on data presented in June. In a November 17 business update, it said it planned to submit an Investigational New Drug application in 2027, followed by a first-in-human study.

Commentary